BRIEF-Palvella Therapeutics Says Top-Line Data From SELVA Expected In Q1 2026

Reuters

09 Jun

BRIEF-<a href="https://laohu8.com/S/PVLA">Palvella Therapeutics</a> Says Top-Line Data From SELVA Expected In Q1 2026

June 9 (Reuters) - Palvella Therapeutics Inc PVLA.O:

PALVELLA THERAPEUTICS RECEIVES INITIAL PROCEEDS FROM FDA ORPHAN PRODUCTS GRANT TO SUPPORT PHASE 3 SELVA TRIAL OF QTORIN™ RAPAMYCIN FOR MICROCYSTIC LYMPHATIC MALFORMATIONS
PALVELLA THERAPEUTICS INC - TOP-LINE DATA FROM SELVA EXPECTED IN Q1 2026
PALVELLA THERAPEUTICS INC - UP TO $2.6 MILLION IN NON-DILUTIVE FUNDING ANTICIPATED OVER GRANT PERIOD
PALVELLA THERAPEUTICS INC - SELVA TRIAL ON TRACK TO REPORT RESULTS IN Q1 2026

Source text: ID:nGNX4Mr30

Further company coverage: PVLA.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2542338109"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542338109\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2542338109?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-09 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542338109","market":"us","top_or_hot":-1,"title":"BRIEF-Palvella Therapeutics Says Top-Line Data From SELVA Expected In Q1 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/PVLA\">Palvella Therapeutics</a> Says Top-Line Data From SELVA Expected In Q1 2026</title></head><body><p><span>June 9 (Reuters)</span><span> - </span>Palvella <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>PVLA.O</span>:</p><ul><li><p>PALVELLA THERAPEUTICS RECEIVES INITIAL PROCEEDS FROM FDA ORPHAN PRODUCTS GRANT TO SUPPORT PHASE 3 SELVA TRIAL OF QTORIN™ RAPAMYCIN FOR MICROCYSTIC LYMPHATIC MALFORMATIONS</p></li><li><p>PALVELLA THERAPEUTICS INC - TOP-LINE DATA FROM SELVA EXPECTED IN Q1 2026</p></li><li><p>PALVELLA THERAPEUTICS INC - UP TO $2.6 MILLION IN NON-DILUTIVE FUNDING ANTICIPATED OVER GRANT PERIOD</p></li><li><p>PALVELLA THERAPEUTICS INC - SELVA TRIAL ON TRACK TO REPORT RESULTS IN Q1 2026</p></li></ul><p>Source text: <span>ID:nGNX4Mr30</span></p><p>Further company coverage: <span>PVLA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Palvella Therapeutics Says Top-Line Data From SELVA Expected In Q1 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Palvella Therapeutics Says Top-Line Data From SELVA Expected In Q1 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-09 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/PVLA\">Palvella Therapeutics</a> Says Top-Line Data From SELVA Expected In Q1 2026</title></head><body><p><span>June 9 (Reuters)</span><span> - </span>Palvella <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>PVLA.O</span>:</p><ul><li><p>PALVELLA THERAPEUTICS RECEIVES INITIAL PROCEEDS FROM FDA ORPHAN PRODUCTS GRANT TO SUPPORT PHASE 3 SELVA TRIAL OF QTORIN™ RAPAMYCIN FOR MICROCYSTIC LYMPHATIC MALFORMATIONS</p></li><li><p>PALVELLA THERAPEUTICS INC - TOP-LINE DATA FROM SELVA EXPECTED IN Q1 2026</p></li><li><p>PALVELLA THERAPEUTICS INC - UP TO $2.6 MILLION IN NON-DILUTIVE FUNDING ANTICIPATED OVER GRANT PERIOD</p></li><li><p>PALVELLA THERAPEUTICS INC - SELVA TRIAL ON TRACK TO REPORT RESULTS IN Q1 2026</p></li></ul><p>Source text: <span>ID:nGNX4Mr30</span></p><p>Further company coverage: <span>PVLA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PVLA","symbol_name":"Palvella Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nTUA64NXSY:1","article_id":"2542338109","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542338109","pubTimestamp":1749470428,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Palvella Therapeutics Says Top-Line Data From SELVA Expected In Q1 2026June 9 (Reuters) - Palvella Therapeutics Inc PVLA.O:PALVELLA THERAPEUTICS RECEIVES INITIAL PROCEEDS FROM FDA ORPHAN PRODUCT","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PVLA":"Palvella Therapeutics","BK4139":"生物科技"},"translate_title":"简介-Palvella Therapeutics表示SELVA的营收数据预计将于2026年第一季度公布","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PVLA":0.9},"content_text":"BRIEF-Palvella Therapeutics Says Top-Line Data From SELVA Expected In Q1 2026June 9 (Reuters) - Palvella Therapeutics Inc PVLA.O:PALVELLA THERAPEUTICS RECEIVES INITIAL PROCEEDS FROM FDA ORPHAN PRODUCTS GRANT TO SUPPORT PHASE 3 SELVA TRIAL OF QTORIN™ RAPAMYCIN FOR MICROCYSTIC LYMPHATIC MALFORMATIONSPALVELLA THERAPEUTICS INC - TOP-LINE DATA FROM SELVA EXPECTED IN Q1 2026PALVELLA THERAPEUTICS INC - UP TO $2.6 MILLION IN NON-DILUTIVE FUNDING ANTICIPATED OVER GRANT PERIODPALVELLA THERAPEUTICS INC - SELVA TRIAL ON TRACK TO REPORT RESULTS IN Q1 2026Source text: ID:nGNX4Mr30Further company coverage: PVLA.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}